Indegene — Q2 FY26 earnings call

Call held 31 Oct 2025

Management summary

Indegene delivered robust double-digit revenue growth in Q2 FY26, driven by strong momentum in its Enterprise segment and significant deal wins. While margins faced temporary pressure from annual wage hikes and strategic investments in GTM and AI, management is prioritizing long-term growth acceleration. The company is aggressively expanding its footprint through M&A and GenAI-led offerings like Tectonic and Cortex.

Highlights

  • Revenue reached ₹8,042 million, representing 17.1% YoY growth and 5.7% sequential growth.

  • Adjusted EBITDA margin (excluding one-time M&A costs) stood at 18.2%, down 200bps QoQ primarily due to annual wage hikes.

  • PAT grew 11.4% YoY to ₹1,021 million, with a PAT margin of 12.7%.

  • Completed two strategic acquisitions in October: BioPharm (US-based, $65M) and WARN & CO (UK-based, £2M upfront).

  • Strong deal wins: 2 large deals with >$3M ACV and 4 deals in the $1M-$3M ACV range.

  • Tectonic (GenAI offering) clocked $2 million in revenue for H1 FY26 from 4 customers.

  • Cash and investments remained healthy at $210 million as of September 30, 2025.

  • Enterprise segment (Commercial and Medical) grew 8.1% QoQ, offsetting a 15.8% degrowth in Brand Activation.

Concerns

  • Near-term Margin Compression

Key financials

  1. Revenue 8,042 Mn +17.1%YoY
  2. EBITDA Margin (Adjusted) 18.2% -2%QoQ
  3. PAT 1,021 Mn +11.4%YoY
  4. Cash and Investments $210 Mn +5%QoQ
  5. DSO 71 days 0%QoQ

What they filed

Q1 FY27: revenue up 33.2%, net profit up 33.3% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue282 287 267 256 307 +9%290 +1%368 +38%341 +33%
EBITDA46 52 40 37 71 +54%38 −27%103 +158%60 +62%
Net profit45 50 54 45 60 +33%35 −30%72 +33%60 +33%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • Enterprise Segment (Commercial & Medical)
    88.5% Revenue Contribution8.1% QoQ Growth
  • Brand Activation
    -15.8% QoQ Growth

Guidance & targets

Margin

  • EBITDA Margin Compression Margin · Near term · Medium confidence 1.5%
    These ahead of the curve investments should accelerate our growth progressively over 6 to 8 quarters, but with EBITDA margins compression in the near term by about 1.5%.

    — Manish Gupta, Chairman and CEO

  • EBITDA Margin Recovery Margin · 6 to 8 quarters · Medium confidence 20%+
    And that would be the other lever to get us back into the range that we have been operating in the past, which is around 20% and a little north of that.

    — Suhas Prabhu, CFO

Revenue

  • Growth Acceleration Revenue · FY26 · Medium confidence Higher than FY25
    But we certainly are looking forward to a growth rate, which is higher than what we saw in the past year and even the start of this year.

    — Suhas Prabhu, CFO

Headcount

  • Employee Growth Rate Headcount · Medium term · High confidence Lesser than revenue growth
    the rate of growth of the number of employees would typically be lesser than the rate of growth of the revenue, and we should see that reflecting in a higher realization at employee level.

    — Suhas Prabhu, CFO

Risks & concerns

  • Near-term Margin Compression

    high

    Planned 1.5% margin hit due to aggressive GTM and AI investments to capture market opportunity.

    Both acknowledged

  • US Drug Pricing Policy (MFN/TrumpRx)

    medium

    Management believes the Pfizer deal provides a template that is not significantly disruptive and clears regulatory overhang.

    Management downplayed

  • US Pharma Tariffs

    medium

    100% tariffs on branded imports could impact clients, though exemptions for US-based manufacturing exist.

    Management acknowledged

  • Brand Activation Segment Volatility

    medium

    The segment degrew 15.8% QoQ due to project completions; management expects a ramp-up in Q3 to partially offset this.

    Analyst acknowledged

Areas of evasion (1)

  • Specific growth guidance for FY27 or the acquisitions beyond qualitative statements.

Q&A highlights

3 direct
Margin Compression and Expense Breakdown Direct
The other expenses that have increased have largely 3 components... approximately USD0.5 million of M&A expenses... IDS marketing event combined with travel cost was the other component... and about $0.25 million of technology costs.

Investors were concerned about the spike in opex; management provided a granular breakdown of one-time vs. recurring costs.

Asked by Ahmed Madha, Unifi Capital

Largest Customer Degrowth Direct
Our largest customer, one of the contracts that was renewed had a change in the mix from onsite to offshore... we would anticipate a reduction in the revenue, while it would actually be in the longer run positive from a margin perspective.

Explains why the top customer revenue declined despite overall growth, framing it as a strategic margin-accretive shift.

Asked by Ahmed Madha, Unifi Capital

BioPharm Revenue Recognition Direct
As per accounting standards, we would have to report gross revenues. However, we would also be disclosing the net revenue.

Clarifies how the new acquisition will impact top-line reporting, as BioPharm has a pass-through revenue component.

Asked by Sameer Dosani, ICICI Prudential AMC

2 min read 5 chapters

Detailed narrative

Strategic Pivot to GenAI and Tectonic Traction

Indegene is aggressively contextualizing GenAI through its proprietary Cortex platform, moving beyond pilots to production. Its Tectonic offering, which focuses on upstream creative processes, generated $2 million in H1 FY26 from 4 paying customers, up from 2 in Q1. Management believes real value in GenAI comes from domain-specific knowledge engineering rather than generic models.

M&A Strategy: BioPharm and WARN & CO

The acquisition of BioPharm for $65 million adds downstream omnichannel campaign execution capabilities, while WARN & CO (£2M upfront) brings UK-based boutique consulting expertise. These acquisitions are expected to be integrated over 2-6 quarters. While they will cause a near-term margin drag of ~1.5%, they are viewed as essential for capturing enterprise-wide commercial engagements.

Margin Headwinds: Wage Hikes and Investments

Q2 margins were impacted by a 2.1% dilution from annual wage hikes effective July 1, 2025. Additionally, the company spent $0.5 million on M&A diligence, $0.5 million on its flagship IDS 2025 event in Philadelphia, and $0.25 million on technology/GenAI subscriptions. Management expects these 'ahead of the curve' investments to compress margins in the short term but drive operating leverage by FY27.

Enterprise Segment Resilience vs. Brand Activation Volatility

The Enterprise segment, contributing 88.5% of revenue, grew 8.1% QoQ, demonstrating strong demand for medical and commercial solutions. Conversely, Brand Activation degrew 15.8% due to the completion of a large project in Q1. Management highlighted a healthy pipeline in Brand Activation and expects a significant ramp-up in Q3 to mitigate recent declines.

Navigating US Policy and Regulatory Shifts

Management addressed evolving U.S. policies, including MFN drug pricing and potential pharma tariffs. They argued that the industry is regaining value as regulatory uncertainty clears. Indegene expects to benefit from tighter DTC marketing regulations as pharma spend shifts from traditional media (TV/print) to the digital and HCP channels where Indegene specializes.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls